Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in...
Bristol Myers' (BMY) BMS-936558, which shrank tumors in advanced lung, kidney and skin cancer in 18%-28% of patients, is at the forefront of treatments designed to enable the body's immune-system to kill cancer cells. Other firms in this "revolution in the making" include Merck (MRK), Roche (RHHBY.PK), Teva (TEVA) and GSK (GSK).
From other sites
Video at CNBC.com (Sep 9, 2015)
Video at CNBC.com (Aug 21, 2015)
at CNBC.com (Jun 1, 2015)
Video at CNBC.com (May 26, 2015)
Video at CNBC.com (Mar 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs